Navigation Links
Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Maintains Target Price of $2.10
Date:12/23/2010

SAN FRANCISCO, Dec. 23, 2010 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Pro-Pharmaceuticals, Inc. (OTC Bulletin Board: PRWP) ("the Company") and maintains its twelve month target price to $2.10. Ross Silver, Principal Analyst at Vista Partners, stated, "DAVANAT®, the Company's lead product candidate, could potentially enhance the efficacy of already approved oncology drugs, such as Avastin®, while also reducing the side effect profile of these drugs. By doing so, patients potentially will live longer and live better and the cost of treatment could be reduced significantly." Mr. Silver goes on to state, "The Company has stated that development of its GR series of compounds, novel carbohydrate compounds intended to treat liver fibrosis, will commence in January 2011. The Company recently entered into a research agreement with the premier liver disease expert in the U.S., Dr. Scott Freidman, at Mt. Sinai Hospital in New York.  Liver disease is considerable and according to the American Liver Foundation, more than 25 million Americans are or have been afflicted with liver and biliary diseases."

To download a FREE copy of the Pro-Pharmaceuticals, Inc. research report, please visit www.vistapglobal.com and click the "download research" icon to gain access to the report.

About Vista Partners:

Vista Partners LLC was founded in 2005 and has offices in California and one in Oregon. We are a Registered Investment Advisor in the States of California and Oregon. Our professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners has built a name for itself in the small cap space due to its selection of profitable investment ideas.

Disclaimer & Disclosure:

For a full list of disclaimers and disclosures, please visit our website www.vistapglobal.com or click here.

Contact:

Ross Silver, 877.215.4813 or info@vistapglobal.com




'/>"/>
SOURCE Vista Partners
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New FORTEO® and EVISTA® Data to be Presented at Premiere Scientific Meeting for Bone and Mineral Research
2. Vista Partners Updates Coverage on Raptor Pharmaceutical Corp.
3. U.S. Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014
4. Chula Vistas Dr. Peter Rullan Adds Alma Lasers Pixel CO2 Laser System to Offer Fractional CO2 Laser Treatments to Patients
5. Biovista Announces the Appointment of Clifford H. Farrah to its Advisory Board
6. New High-Resolution Computer Tomography Data Demonstrates EVISTA(R)s Effect on Bone Quality in Osteoporotic Patients
7. Watson Confirms EVISTA(R) Patent Challenge
8. Biovista Inc. and FDA to Collaborate on a Medication Safety Initiative
9. Biovista Inc. Named Top Innovator in Life Sciences
10. Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis
11. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , Aug. 15, 2017  AOTI Inc. announced today that its ... Inc., has recently opened a New York City Office in ... of its unique Topical Wound Oxygen (TWO 2 ) homecare therapy. ... Accreditation Commission for Health Care (ACHC) under the company,s DMEPOS accreditation ... ...
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
(Date:8/7/2017)... Mich. , Aug. 7, 2017 Diplomat Pharmacy, ... of Joel Saban as president, effective Aug. 7, ... Urick has decided to pursue other interests and will ... "During his tenure, Paul has served us in multiple leadership ... Specialty Pharmacy in Jun. 2015 and has provided decisive, strategic ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... ... Maury Regional Health has announced a large-scale adoption of AccuVein vein visualization ... Regional Medical Center is making vein visualization part of their standard of care. , ... importantly, helps our staff members locate a vein that will provide good access to ...
(Date:8/16/2017)... ... August 16, 2017 , ... A global leader in the treatment ... clinics in all 29 Indian states—bringing the country one step closer to eliminating clubfoot ... the nonprofit organization is on track to enroll 10,000 children in the clubfoot treatment ...
(Date:8/16/2017)... ... , ... Fusion Flix Inc., a Telly Award Winning, Non Profit Corporation has ... viewers in a partnership with the Amazon Video Direct Streaming Distribution Platform. , Their ... Ray disc in 2018. Proceeds will be going to further health research. , ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... TopConsumerReviews.com recently ... Lab Testing . , The healthcare industry in the United States has undergone ... are the days of needing to have a doctor’s order to get a blood ...
(Date:8/16/2017)... , ... August 16, 2017 , ... First Choice ... States, named Dr. Douglas J. Harrison, as the new Medical Director of its Sienna ... new facility Medical Director of our Sienna Plantation location,” said Dr. Michael (Derek) Caraway, ...
Breaking Medicine News(10 mins):